These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 39333557)

  • 1. Elevated α-1,2-mannosidase MAN1C1 in glioma stem cells and its implications for immunological changes and prognosis in glioma patients.
    Batara DC; Kim HJ; Phan LT; Kim M; Son YO; Lee S; Park SI; Choi YS; Beck S; Kim SH
    Sci Rep; 2024 Sep; 14(1):22159. PubMed ID: 39333557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis.
    Zhai Y; Li G; Li R; Chang Y; Feng Y; Wang D; Wu F; Zhang W
    Front Immunol; 2020; 11():581209. PubMed ID: 33133100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages.
    Dong M; Zhang X; Peng P; Chen Z; Zhang Y; Wan L; Xiang W; Liu G; Guo Y; Xiao Q; Wang B; Guo D; Zhu M; Yu X; Wan F
    Cancer Lett; 2024 May; 590():216801. PubMed ID: 38479552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion.
    Gangoso E; Southgate B; Bradley L; Rus S; Galvez-Cancino F; McGivern N; Güç E; Kapourani CA; Byron A; Ferguson KM; Alfazema N; Morrison G; Grant V; Blin C; Sou I; Marques-Torrejon MA; Conde L; Parrinello S; Herrero J; Beck S; Brandner S; Brennan PM; Bertone P; Pollard JW; Quezada SA; Sproul D; Frame MC; Serrels A; Pollard SM
    Cell; 2021 Apr; 184(9):2454-2470.e26. PubMed ID: 33857425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
    Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
    Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma.
    Jeong HY; Kim HJ; Kim CE; Lee S; Choi MC; Kim SH
    Int J Neurosci; 2021 Jan; 131(1):7-14. PubMed ID: 32075484
    [No Abstract]   [Full Text] [Related]  

  • 10. B3GNT5 is a novel marker correlated with stem-like phenotype and poor clinical outcome in human gliomas.
    Jeong HY; Park SY; Kim HJ; Moon S; Lee S; Lee SH; Kim SH
    CNS Neurosci Ther; 2020 Nov; 26(11):1147-1154. PubMed ID: 32677340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.
    Binder ZA; Siu IM; Eberhart CG; Ap Rhys C; Bai RY; Staedtke V; Zhang H; Smoll NR; Piantadosi S; Piccirillo SG; Dimeco F; Weingart JD; Vescovi A; Olivi A; Riggins GJ; Gallia GL
    PLoS One; 2013; 8(10):e75945. PubMed ID: 24146797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements.
    Fei X; Wu J; Tian H; Jiang D; Chen H; Yan K; Wang Y; Zhao Y; Chen H; Xie X; Wang Z; Zhu W; Huang Q
    Cancer Biomark; 2024; 41(1):1-24. PubMed ID: 39240627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
    Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
    J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis.
    Tian R; Wang J; Yan H; Wu J; Xu Q; Zhan X; Gui Z; Ding M; He J
    Oncogene; 2017 Oct; 36(42):5861-5873. PubMed ID: 28628119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quiescent stem cell marker genes in glioma gene networks are sufficient to distinguish between normal and glioblastoma (GBM) samples.
    Mukherjee S
    Sci Rep; 2020 Jul; 10(1):10937. PubMed ID: 32616845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
    Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
    Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COL8A1 is a potential prognostic biomarker associated with migration, proliferation, and tumor microenvironment in glioma.
    Liu M; Liang W; Su Y; Wen Y; Qi J; Wang L; Su S; Zhao J; Shan J; Wang J
    Exp Cell Res; 2024 Jun; 439(1):114076. PubMed ID: 38719174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
    Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
    Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma.
    Giordano C; Marrone L; Romano S; Della Pepa GM; Donzelli CM; Tufano M; Capasso M; Lasorsa VA; Quintavalle C; Guerri G; Martucci M; Auricchio A; Gessi M; Sala E; Olivi A; Romano MF; Gaudino S
    Cancer Res Commun; 2024 May; 4(5):1296-1306. PubMed ID: 38651817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SENP1-Mediated deSUMOylation Regulates the Tumor Remodeling of Glioma Stem Cells Under Hypoxic Stress.
    Wen P; Li H; Liu L; Liu X; Xu Z; Dong J
    Technol Cancer Res Treat; 2024; 23():15330338241257490. PubMed ID: 38803001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.